Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

M.J. Rodrigo; MJ Cardiel; JM Fraile; S Mendez-Martinez; T Martinez-Rincon; M  Subias; V. Polo; Jesus Ruberte Paris; T. Ramírez; E Vispe; C. Luna; J.A. Mayoral; Elena García-Martin

Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

M.J. Rodrigo, MJ Cardiel, JM Fraile, S Mendez-Martinez, T Martinez-Rincon, M Subias, V. Polo, Jesus Ruberte Paris, T. Ramírez, E Vispe, C. Luna, J.A. Mayoral, Elena García-Martin^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

16 Citations (Scopus)

Original language	English
Pages (from-to)	21;8(22):6246-6260. doi: 10.1039/d0bm01013h
Journal	Biomaterials Science
Volume	21
Issue number	8(22)
Publication status	Published - Nov 2020

Cite this

Rodrigo, M. J., Cardiel, MJ., Fraile, JM., Mendez-Martinez, S., Martinez-Rincon, T., Subias, M., Polo, V., Ruberte Paris, J., Ramírez, T., Vispe, E., Luna, C., Mayoral, J. A., & García-Martin, E. (2020). Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model. Biomaterials Science, 21(8(22)), 21;8(22):6246-6260. doi: 10.1039/d0bm01013h.

@article{5a12d9ebc54d42caba5bc6bded7d674b,

title = "Brimonidine-LAPONITE{\textregistered} intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model",

author = "M.J. Rodrigo and MJ Cardiel and JM Fraile and S Mendez-Martinez and T Martinez-Rincon and M Subias and V. Polo and \{Ruberte Paris\}, Jesus and T. Ram{\'i}rez and E Vispe and C. Luna and J.A. Mayoral and Elena Garc{\'i}a-Martin",

year = "2020",

month = nov,

language = "English",

volume = "21",

pages = "21;8(22):6246--6260. doi: 10.1039/d0bm01013h",

journal = "Biomaterials Science",

issn = "2047-4830",

publisher = "Royal Society of Chemistry",

number = "8(22)",

}

Rodrigo, MJ, Cardiel, MJ, Fraile, JM, Mendez-Martinez, S, Martinez-Rincon, T, Subias, M, Polo, V, Ruberte Paris, J, Ramírez, T, Vispe, E, Luna, C, Mayoral, JA & García-Martin, E 2020, 'Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model', Biomaterials Science, vol. 21, no. 8(22), pp. 21;8(22):6246-6260. doi: 10.1039/d0bm01013h.

Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model. / Rodrigo, M.J.; Cardiel, MJ; Fraile, JM et al.
In: Biomaterials Science, Vol. 21, No. 8(22), 11.2020, p. 21;8(22):6246-6260. doi: 10.1039/d0bm01013h.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

AU - Rodrigo, M.J.

AU - Cardiel, MJ

AU - Fraile, JM

AU - Mendez-Martinez, S

AU - Martinez-Rincon, T

AU - Subias, M

AU - Polo, V.

AU - Ruberte Paris, Jesus

AU - Ramírez, T.

AU - Vispe, E

AU - Luna, C.

AU - Mayoral, J.A.

AU - García-Martin, Elena

PY - 2020/11

Y1 - 2020/11

UR - https://www.scopus.com/pages/publications/85096080019

M3 - Article

SN - 2047-4830

VL - 21

SP - 21;8(22):6246-6260. doi: 10.1039/d0bm01013h

JO - Biomaterials Science

JF - Biomaterials Science

IS - 8(22)

ER -

Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

Other files and links

Cite this